Gland Pharma Limited (GLAND) - Total Liabilities

Latest as of March 2026: Rs21.53 Billion INR ≈ $232.83 Million USD

Based on the latest financial reports, Gland Pharma Limited (GLAND) has total liabilities worth Rs21.53 Billion INR (≈ $232.83 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Gland Pharma Limited - Total Liabilities Trend (2017–2026)

This chart illustrates how Gland Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Gland Pharma Limited to evaluate short-term liquidity relative to the company's equity base.

Gland Pharma Limited Competitors by Total Liabilities

The table below lists competitors of Gland Pharma Limited ranked by their total liabilities.

Company	Country	Total Liabilities
Federated Investors Inc B NYSE:FHI	USA	$931.47 Million
Parq Arauco SN:PARAUCO	Chile	CL$2.18 Trillion
Canadian Apartment Properties Real Estate Investment Trust TO:CAR-UN	Canada	CA$6.42 Billion
Carnival Plc ADS NYSE:CUK	USA	$38.52 Billion
Xinhu Zhongbao Co Ltd SHG:600208	China	CN¥51.51 Billion
Independence Realty Trust Inc NYSE:IRT	USA	$2.58 Billion
BNK Financial Group Inc KO:138930	Korea	₩149.85 Trillion
AUTO1 Group SE F:AG1	Germany	€1.96 Billion

Liability Composition Analysis (2017–2026)

This chart breaks down Gland Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gland Pharma Limited (GLAND) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.68	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.21	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.17	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Gland Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Gland Pharma Limited (2017–2026)

The table below shows the annual total liabilities of Gland Pharma Limited from 2017 to 2026.

Year	Total Liabilities	Change
2026-03-31	Rs21.53 Billion ≈ $232.83 Million	+3.80%
2025-03-31	Rs20.74 Billion ≈ $224.31 Million	+7.06%
2024-03-31	Rs19.37 Billion ≈ $209.52 Million	+136.61%
2023-03-31	Rs8.19 Billion ≈ $88.55 Million	+21.13%
2022-03-31	Rs6.76 Billion ≈ $73.11 Million	+14.03%
2021-03-31	Rs5.93 Billion ≈ $64.11 Million	+34.80%
2020-03-31	Rs4.40 Billion ≈ $47.56 Million	-33.52%
2019-03-31	Rs6.62 Billion ≈ $71.54 Million	+27.44%
2018-03-31	Rs5.19 Billion ≈ $56.14 Million	+35.21%
2017-03-31	Rs3.84 Billion ≈ $41.52 Million	--

About Gland Pharma Limited

NSE:GLAND India Drug Manufacturers - Specialty & Generic

Market Cap

$3.89 Billion

Rs359.40 Billion INR

Market Cap Rank

#4273 Global

#180 in India

Share Price

Rs2178.70

Change (1 day)

-1.55%

52-Week Range

Rs1596.80 - Rs2334.00

All Time High

Rs4272.42